Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Can-Fite Biopharma

    - PMLiVE

    AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial

    Follicular lymphoma affects around 15,000 people in the US every year

    - PMLiVE

    AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

    Around 700,000 people in the US are living with some form of the autoimmune disease

    - PMLiVE

    AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer

    Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK

    - PMLiVE

    AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

    ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

    - PMLiVE

    AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition

    The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases

    - PMLiVE

    AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies

    The companies will focus on developing therapeutics across neuroscience, immunology and oncology

    - PMLiVE

    AbbVie’s Emrelis granted FDA accelerated approval to treat advanced lung cancer

    An estimated 226,650 people will be diagnosed with lung cancer in the US this year

    - PMLiVE

    AbbVie’s JAK inhibitor Rinvoq granted FDA approval to treat giant cell arteritis

    The drug could allow patients to taper off steroids and achieve sustained remission

    - PMLiVE

    AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis

    The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

    - PMLiVE

    AbbVie’s Elahere shows consistent survival benefits in late-stage ovarian cancer trial

    Approximately 20,000 cases of the disease are diagnosed in the US every year

    - PMLiVE

    AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn

    The companies will aim to develop tumour-activated immunotherapies, including masked T-cell engagers

    - PMLiVE

    AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections

    Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links